期刊
SCIENTIFIC REPORTS
卷 8, 期 -, 页码 -出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41598-018-27643-3
关键词
-
资金
- National Institute of Health [K08CA155035]
- Melanoma Research Alliance [273654]
- Dattels Fund
- Melanoma Coalition
- L'Oreal Italia per le Donne e la Scienza
- Biomedical Technology Research Centers Program of the NIH National Institute of General Medical Sciences, NIH NIGMS [8P41GM103481]
- Howard Hughes Medical Institute
- Verein fur Dermatologie und Venerologie Rudolfstiftung
- European Academy of Dermatology and Venereology [RF 2016-014]
Despite major advances in targeted melanoma therapies, drug resistance limits their efficacy. Long noncoding RNAs (lncRNAs) are transcriptome elements that do not encode proteins but are important regulatory molecules. LncRNAs have been implicated in cancer development and response to different therapeutics and are thus potential treatment targets; however, the majority of their functions and molecular interactions remain unexplored. In this study, we identify a novel cytoplasmic intergenic lincRNA (MIRAT), which is upregulated following prolonged MAPK inhibition in NRAS mutant melanoma and modulates MAPK signaling by binding to the MEK scaffold protein IQGAP1. Collectively, our results present MIRAT's direct modulatory effect on the MAPK pathway and highlight the relevance of cytoplasmic lncRNAs as potential targets in drug resistant cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据